ecancermedicalscience

Research

Subcutaneous versus intravenous administration of Trastuzumab: a minimization cost analysis with real world data from a reference cancer centre in Peru

31 May 2024
Iris Otoya, Natalia Valdiviezo, Katia Roque, Zaida Morante, Tatiana Vidaurre, Silvia P. Neciosup, Mónica J. Calderón, Henry L. Gomez

Breast cancer (BC) is a global concern, with Peru experiencing a high incidence and mortality. Trastuzumab, a crucial treatment for human epidermal growth factor receptor 2-positive BC, is administered intravenously or subcutaneously (SC). This study evaluates the costs associated with both methods at Peru's Instituto Nacional de Enfermedades Neoplásicas. Real data indicate that SC administration reduces treatment costs by approximately S/15,049.09. Cross-continental comparisons highlight a global trend favouring SC administration for efficiency and cost-effectiveness. The analysis provides insights for informed decision-making in resource-constrained healthcare settings like Peru, emphasising the need to consider local contexts in optimising oncology care.

Related Articles

Berenice Freile, Andrés Rodriguez, Greta Catani, Marcos Bortz, Luisina Bruno, Juan M O’Connor, Federico Esteso
Joaquin Fernandez-Alberti, Alex R Villaalta López, Guillermo Scolari, Alejandro Iotti, Marcelo Featherston
Bharath B Gangadharaiah, Ghazal Tansir, Sameer Rastogi, Simran Kaur, Vikas Garg, Ekta Dhamija, Adarsh Barwad, Shivanand Gamanagatti, Sandeep Bhoriwal, Maroof A Khan
Izaberen Sampaio Estevam, Mariana Macambira Noronha, Júlia Matos Dubanhevitz, Eric Lima Freitas Mota, Ígor Giordan Duarte Jorge, Conceição Aparecida Dornelas, Diane Isabelle Magno Cavalcante, Georgia Fiuza Alencar Araripe, Márcio Marcondes Vieira
Agodirin Olayide, Chijioke Chijindu, Mustapha Fathi, Rahman Ganiyu, Olatoke Samuel, Olaogun Julius, Akande Halima